

# Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study

NCT06787014

---

**Status** RECRUITING  
**Sponsor** Insel Gruppe AG, University Hospital Bern  
**Enrollment** 3,200 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- All patients with siNET and non-curative metastatic disease between 01.01.2005 and 31.12.2021 will be included.

### Exclusion (2)

- All patients with siNET G3, resectable metastatic disease and/or non-resectable primary tumor at initial diagnosis will be excluded. Furthermore, symptomatic patients (small intestinal obstruction, bleeding) or when imaging suggests that obstruction will probably occur (bowel dilatation, mesenteric fibrosis) at initial diagnosis will be excluded. Patients with diarrhea, flushing, or abdominal pain will not be excluded.
- Patients with a documented rejection for a further use of their data for scientific purposes will also be excluded.

## Locations (1 total)

---

UHI Berne, Bern, Switzerland